Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity (2012 - 2026)

Agios Pharmaceuticals has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 23.82% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (down 7.68% YoY), and the FY2025 full-year result was $1.3 billion, down 22.0% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.8 billion in Q3 2024, with the low at $773.1 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 46.32% — and 2025, when it soared 90.31%.
• Agios Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then fell by 24.35% to $937.1 million in 2023, then jumped by 77.48% to $1.7 billion in 2024, then decreased by 22.0% to $1.3 billion in 2025, then declined by 8.65% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.